The targeted delivery of radionuclides to tumours holds great promise for diagnosis and
treatment of malignant neoplasms. The development of scaffold proteins has significantly …

Targeting of human epidermal growth factor type 2 (HER2) using monoclonal antibodies,
antibody-drug conjugates and tyrosine kinase inhibitors extends survival of patients with …

The field of targeted therapeutics has benefitted immeasurably from the development of high-
affinity antibodies. These important ligands have facilitated the development of effective …

The use of radiolabelled antibodies was proposed in 1970s for staging of malignant
tumours. Intensive research established chemistry for radiolabelling of proteins and …

Monoclonal antibodies are the classical basis for targeted therapy, but the development of
alternative binding proteins has made it possible to use non-immunoglobulin proteins as …

Studies concerning the development of radiopharmaceuticals based on the Tc (I) carbonyl
core are considered from the coordination-chemical viewpoint. The coordination behavior of …

Radionuclide molecular imaging of HER2 expression in disseminated cancer enables
stratification of patients for HER2-targeted therapies. DARPin G3, a small (14 kDa) …

Designed ankyrin repeat proteins (DARPins) are small engineered scaffold proteins that can
be selected for binding to desirable molecular targets. High affinity and small size of …

According to the most recent epidemiological studies, breast cancer shows the highest
incidence and the second leading cause of death in women. Cancer progression and …

В настоящем обзоре обсуждается относительно новый класс направленных адресных
молекул, активно исследующийся в отношении радионуклидной диагностики и лечения …